Human Peripheral Blood Leukopaks and Mobilized Leukopaks are enriched leukapheresis products whereby mononuclear cells (MNCs), plasma, and platelets are separated and collected from the granulocytes and red blood cells. The MNCs are composed of lymphocytes (T cells, B cells, and NK cells), monocytes, dendritic cells, and stem/progenitor cells. These cells are critical components of the immune system and play key roles in the humoral and cell-mediated immune responses.
Although both types of Leukopaks offer an abundant amount of hematopoietic cells, each has their own unique properties, making them ideal for specific applications/studies.
Peripheral Blood Leukopaks provide an enriched mononuclear cell fraction (>90%) with low granulocytes and red blood cells as compared to buffy coats obtained from density gradient centrifugation of whole blood. This highly enriched MNC fraction requires minimal downstream processing (i.e. ficoll) and can be used directly for isolating high-yields of immune cells, such as CD4+ T cells, CD8+ T cells, CD19+ B cells, monocytes, and a variety of other immune cells and subsets. This allows researchers greater reproducibility of experiments from a single donor (minimizing donor-to-donor variation), scalability of experiments, and a decrease in cell variability. In addition, up to 12 Leukopak collections can be performed on the same donor in a given year, providing an ample amount of MNCs for large-scale cell-based studies in the areas of immunology, infectious disease, hematological malignancies, vaccine development, and high-throughput screening.
High-quality Leukopaks will provide a rich MNC population with minimal granulocyte contamination:
– Highly-enriched MNCs
– Low granulocyte
– Low hematocrit
– 0.1 to 0.2% CD34+ cells
– >90% viability